- Bora Pharmaceuticals has completed the acquisition of Emergent BioSolutions’ sterile manufacturing facility in Baltimore, expanding its drug product fill/finish capabilities.
Bora Pharmaceuticals Co. Ltd. has completed the acquisition of Emergent BioSolutions’ sterile manufacturing facility located in Baltimore-Camden, Maryland. This acquisition expands Bora’s capabilities in drug product manufacturing, particularly in the area of sterile injectables, adding to its existing biologics drug substance capabilities.
The 87,000-square-foot facility offers a range of services, including clinical and commercial non-viral aseptic fill/finish for vials and pre-filled syringes, lyophilization, and formulation development. The site features four fill lines dedicated to these processes.
Bobby Sheng, Chairman and CEO of Bora Pharmaceuticals, commented on the acquisition, stating, “The Camden facility extends our presence in North America, expands our offering for our biologics customers, and advances us further in our goal to become a full service global CDMO.” He also emphasized the company’s commitment to enhancing the capabilities of the newly acquired site and integrating the Camden team into Bora’s global operations.
Earlier this year, Bora Pharmaceuticals also acquired Upsher-Smith Laboratories, a generics manufacturer based in Minnesota, further broadening its North American presence with two facilities focused on oral dose production. With this latest acquisition, Bora’s global contract development and manufacturing organisation (CDMO) network now spans ten facilities worldwide, catering to various dose forms and delivery technologies.
Overview of outsourcing trends 
